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1. Introduction 
Chronic kidney disease (CKD) is increasingly recognized as a major public health problem. 
CKD is often under-diagnosed and under-treated because the disease tend to be latent at 
onset and progress slowly. High blood pressure, diabetes and primary or secondary 
glomerulonephritis are the main causes of CKD. Today, various diabetic and non-diabetic 
glomerulopathies form the main contingent of renal replacement therapy (RRT) patients. 
The above named diseases, therefore, present a major problem encountered in the practice 
of nephrology. CKD affects many more people than we would even imagine: 1 out of 10 
adults in the world have some form of kidney damage. Therefore, early detection and 
prevention the progression of people with CKD who are also at very high cardiovascular 
risk, is extremly important challenge and goal especially for all internal medicine 
practitioners. 
CKD represents a progressive, irreversible decline in glomerular filtration rate. Progressive 
renal function loss is a common phenomenon in renal failure irrespectively of the 
underlying cause of the kidney disease (Brenner and Anderson 1992; Ots, Pechter et al. 
2000). The kidney is able to adapt to damage by increasing the filtration rate in the 
remaining normal nephrons, a process called adaptive hyperfiltration. As a result, the 
patient with mild renal insufficiency often has a normal or near-normal serum creatinine 
concentration. Adaptive hyperfiltration, although initially beneficial, appears to result in 
long-term damage to the glomeruli of the remaining nephrons, which is manifest by 
proteinuria and progressive renal insufficiency. This process appears to be responsible for 
the development of renal failure among those in whom the original illness is either inactive 
or cured (Post and Rose 2007). Most chronic nephropathies unfortunately lack a specific 
treatment and progress relentlessly to end stage renal disease. The therapy for the 
modulation of the renal disease progression has been improved lately because several new 
antihypertensive drugs which block renin–angiotensin system (RAS) have been introduced 
to clinical practice, e.g. angiotensin converting enzyme inhibitors (ACEI) (Rubin, Antonaccio 
et al. 1978) and angiotensin II receptor antagonists (AT1RA). ACEI proved its effectiveness in 
the treatment of essential hypertension and congestive heart failure. Later, studies on 
experimental (Anderson, Meyer et al. 1985) and human diabetic (Lewis, Hunsicker et al. 
1993; Brenner, Cooper et al. 2001) and non-diabetic (Maschio, Alberti et al. 1996) renal 
diseases revealed that the progression of the renal disease can be slowed by RAS blocking 
treatment that modulates the hemodynamic and non-hemodynamic factors contributing to 
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the progression. RAS blocking agents have been shown to be renoprotective and, therefore, 
prescribed not only for antihypertensive but also for renoprotective purposes in diabetic 
nephropathy and in other chronic glomerular diseases. The cost of the advanced renal 
failure and renal replacement therapy is enormous. Therefore, early diagnosis and optimal 
management of CKD as well as premature atherosclerosis affords many challenges for 
internal medicine practitioners to help to maintain health and life quality among the 
population at risk. 
 
2. Epidemiology of CKD 
There is a rising incidence and prevalence of kidney failure and the worldwide epidemic of 
CKD shows no signs of abating in the near future. The exact reasons for the growth of the 
end-stage renal disease are unknown. Changes in the demographics of the population, 
differences in disease burden among different racial groups and under-recognition of earlier 
stages and of risk factors for CKD may partially explain this growth. Recent trends show 
that the rate of increase of new cases of both diabetic and all-cause end-stage renal disease 
(ESRD) has progressively levelled off in many countries. It is therefore currently impossible 
to predict the long-term trend of RRT in Europe (Zoccali, Kramer et al.). Zocalli et al have 
recently acknowledged that in the large, diachronic scenario of systemic epidemiology, CKD 
is a component of a new epidemic of diseases that, over the twentieth century, replaced 
malnutrition and infection as leading causes of mortality in the population (Zoccali, Kramer 
et al.). Neoplasia, cardiovascular and respiratory diseases and diabetes are ascending the 
priority rank in the global-health agenda. These diseases reduce life expectancy and 
engender disability in all population strata including the poorest segment of the population, 
a stratum still considered to be mainly hit by infectious diseases (Zoccali, Kramer et al.). 
The ERA-EDTA Registry (http://www.era-edta-reg.org) collects individual and aggregated 
data from national and/or regional renal registries in Europe and countries bordering the 
Mediterranean Sea. The individual patient data are used for epidemiological analysis to 
calculate incidence, prevalence and patient survival. These are published in the Registry 
annual reports together with aggregated incidence and prevalence data that are received 
from other European countries. 
Diabetes is one of the commonest causes of CKD beside hypertension and 
glomerulonephritis in many countries (Locatelli, D'Amico et al. 2001; Moeller, Gioberge et 
al. 2002; Jager and van Dijk 2007). The major groups of diseases leading to ESRD are diabetic 
nephropathy, hypertension, glomerulonephritis, chronic pyelonephritis and polycystic 
kidney disease. In different countries the proportions of these diseases as a cause of renal 
failure vary: e.g. prevalent patients of diabetic nephropathy form from RRT patients in Italy 
12%, in Estonia 22%, in Finland and Poland 24%, in Germany 23%, in England 12%, in Japan 
30%, and in USA 37%. Very few of the causes of CKD are completely curable. 
Glomerulonephritis form 22-24% from prevalent renal replacement therapy (RRT) patients 
in Estonia, Germany, Poland or Finland but only 11-12% in France, Italy or England.  
The use of RRT varies in different countries. The prevalence of RRT patients/million 
inhabitants 2005 was very different worldwide: in Estonia 394, in Finland 675, in Sweden 
774, in Germany 1057, in Spain 869, in England 671 or in USA 1590 . 
It has been shown that CKD affects men more often than women. For example, according to 
the Finnish Registry for Kidney Diseases the prevalence of RRT in men was 898 and in 
 
women 553/million inhabitants in 2006. Since 1996, the prevalence of RRT has increased 
faster among men (63%) than among women (44%). The prevalence among the elderly is 
growing fast: in the age group 75+ years, the prevalence of RRT has increased by almost 
250% during the past ten years and 70% during the past five years. In the younger age 
groups, the prevalence has increased 10–61% in ten years and 4–14% in five years. 
 
3. Progression of CKD 
Several immunologic as well as non-immunologic mechanisms are related to the progression 
of kidney diseases (Klahr, Schreiner et al. 1988; Remuzzi, Ruggenenti et al. 1997). The nature of 
the progressive renal damage with various etiologies includes well-known factors where 
hemodynamics (Hostetter, Olson et al. 1981), participation of RAS and progressive proteinuria 
(Williams and Coles 1994)play central roles (Remuzzi, Ruggenenti et al. 1997). 
In chronic renal failure, after the loss of a critical number of nephrons, the remaining 
nephrons undergo compensatory functional and structural adaptations. During this process, 
the surviving nephrons lose the capacity to autoregulate glomerular flows and pressures 
and become vulnerable to the effects of systemic hypertension, which is readily 
accompanied by glomerular hypertension, hyperfiltration and hypertrophy (Hostetter, 
Olson et al. 1981). Angiotensin II is important in mediating glomerular hemodynamics and 
contributes to the rise of intraglomerular and systemic blood pressure. In essential and 
secondary hypertensive states, at a certain stage, an increase in intraglomerular capillary 
pressure plays a role in the acceleration of the loss in renal function. Hypertension is a risk 
factor for the development of atherosclerosis (Ross 1986), for all-cause mortality (O'Donnell, 
Ridker et al. 1997), but also of glomerulosclerosis in various etiologies (Klag, Whelton et al. 
1996). These two processes share several common mechanism (Diamond 1991), e.g. 
hormonal, cellular and molecular events although these have not been entirely elucidated. 
Central to the pathogenesis of atherosclerosis is the interaction of blood cells and endothelial 
cells with subsequent proliferation of smooth muscle cells and enhanced production of 
collagen. The mechanisms that appear to be responsible for this increased proliferative 
response are growth factors, cytokines, and local alterations in the extracellular matrix 
proteins. There is increasing evidence that atherosclerosis should be viewed fundamentally 
as an inflammatory disease (Raines and Ross 1997) where risk factors such as hypertension, 
humoral factors (Raij 1991), hyperlipidemia (Devaraj and Jialal 1996), lipid deposition in 
vessels and later development of atherosclerotic lesions play central roles in the progression. 
As in the case of atherosclerosis, there is an inflammatory content involved in kidney 
fibrosis in human (Noronha, Niemir et al. 1995) or experimental glomerulonephritides 
(Lloyd, Minto et al. 1997), and even in classical glomerulosclerotic models previously 
thought to be non-inflammatory, e.g. remnant kidney (Schiller and Moran 1997). Infiltration 
of mononuclear leucocytes in glomerular and tubulointerstitial areas, upregulation of 
proinflammatory cytokines and growth factors after the initiation of the disease play 
important roles in the progression (Schiller and Moran 1997). The glomerulosclerosis 
process includes mesangial expansion with mesangial cell proliferation, mesangial foam cell 
accumulation, tissue necrosis, and eventual sclerosis. Substances that interfere with the 
interaction between the different cell types, such as endothelial cells, macrophages, and 
platelets, and with the proliferative responses of both vascular and mesangial cells may be 
of therapeutic value in both diseases. 
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Data about the upregulation of various proinflammatory cytokines are similarly available 
for other non-inflammatory renal diseases such as diabetic nephropathy and certainly for 
human nephropathies (Niemir, Stein et al. 1995; Kato, Luyckx et al. 1999). Wagner et al. 
provided technical evidence that using PCR may give a possibility in the future to analyze 
expressions of genes which may contribute to renal damage in human biopsies (Wagner, 
Drab et al. 1994). Knowing key molecules, which play a pathophysiological role or serve as 
markers for the progression of renal disease may allow more precise staging of the disease 
and better indicate therapeutic needs in particular diseases. Cytokines have also been 
demonstrated in other biological samples, e.g. urine. The results of Noh et al. (Noh, Wiggins 
et al. 1993) suggest that measurements of urinary activity of transforming growth factor beta 
(TGF-β) at certain critical stages of the disease could be useful in predicting the progression 
to end-stage renal disease with fibrosis. Therefore, a urine test for the detection of particular 
growth factors might serve as a helpful non-invasive adjunct in monitoring the response to 
therapy. Much interest has been paid to TGF-β because the key action of this growth factor 
is the induction of the extracellular matrix protein production. Specific matrix proteins are 
known to be induced by TGF-β, which were increased in experimental kidney disease rat 
glomeruli. For instance, Yamamoto et al. has shown the correlation of TGF-β (Yamamoto, 
Noble et al. 1994) with the accumulation of extracellular matrix proteins in the 
glomerulonephritis model and the treatment with the inhibitor of TGF-β prevents scarring 
of the kidney. Yamamoto et al. were able to show that in the rats given a second antibody 
injection of an antibody reactive with glomerular mesangial cells, 1 week later, the 
glomerular expression of TGF-β-1 mRNA and TGF-β-1 protein remained elevated for 18 
weeks. It was associated with a large infiltration of mononuclear cells with staining features 
of fibroblastic/myofibroblastic cells, strongly expressing TGF-β in the tubulointerstitium of 
the kidney (Yamamoto, Noble et al. 1994). A single injection of antibody resulted only in the 
transient upregulation of TGF-β. These data suggest that sustained TGF-β expression 
contributes to the development of progressive kidney fibrosis. TGF-β, monocyte 
chemoattractant protein-1 (MCP-1) mRNA and protein expression as well as macrophage 
infiltration dynamics have been investigated in experimental diabetic nephropathy (Kato, 
Luyckx et al. 1999). In these studies sustained TGF-β and MCP-1 overexpression was also 
observed. This particular gene expression was closely associated with the extent of 
macrophage infiltration and proteinuria (Kato, Luyckx et al. 1999).  
Much attention has recently been paid to the importance of persistent proteinuria, an 
independent risk factor of renal disease progression (Klahr, Schreiner et al. 1988; Williams 
and Coles 1994). Proteins filtered through the glomerular capillary in excessive amount 
activate proximal tubular cells to upregulate chemokines mainly via activation of NF-
kappaB-dependent pathway. The association between proteinuria and interstitial 
accumulation of inflammatory cells via activation of transcription factors and 
overexpression of chemokines has been established both experimentally and in human 
proteinuric nephropathies (Zoja, Garcia et al. 2009). Biochemical events associated with 
tubular cell activation in response to protein stress include upregulation of inflammatory 
and vasoactive genes such as MCP-1 and endothelins. These molecules are associated with a 
tubulointerstitial inflammatory reaction that in most forms of glomerulonephritis 
consistently proceeds renal scarring. Adequate early antiproteinuric therapy may arrest the 
progression of the renal disease or even lead to the regression of the disease. Also, 
disturbances in lipid metabolism, participation of cellular and molecular factors and 
 
subsequent accumulation of extracellular matrix components with the development of 
kidney fibrosis are closely related to the progression (Floege, Burns et al. 1992; Remuzzi, 
Ruggenenti et al. 1997). Clarification of the mechanisms underlying progression of 
proteinuric nephropathies received significant input from the generation of transgenic and 
knockout animals and from novel approaches to block mediators of injury. Recent findings 
have shown that gene targeting in rodents identified podocyte loss as central event in the 
development of glomerulosclerosis. The trigger is dysfunction or absence of podocyte 
molecules that stabilize the slit diaphragm or anchor foot processes to the basement 
membrane. Sustained injury of the glomerular barrier to proteins is transmitted to the 
tubulointerstitial compartment leading to inflammation and fibrosis. Blocking NF-kappaB 
activity and chemokine signals in the kidney effectively interrupts such process. Growth 
factors produced by tubular cells and inflammatory cells contribute to interstitial 
fibrogenesis via myofibroblast activation. This knowledge will provide basis for novel 
interventions to protect the podocyte in chronic progressive glomerulopathies and to halt 
renal scarring and loss of function (Zoja, Abbate et al. 2006). 
 
4. CKD progression prevention strategies 
Various therapies have been studied which may protect kidneys against progressive injury 
including at least two experimentally and clinically confirmed strategies: a reduction in 
protein intake (Brenner, Meyer et al. 1982) or a lowering in blood pressure (Anderson, 
Meyer et al. 1985). Systemic hypertension complicates experimental glomerulosclerosis and 
the clinical course of patients with chronic renal failure, and, if inadequately controlled, may 
hasten the deterioration of renal function (Klag, Whelton et al. 1996). In diabetic and non-
diabetic patients with proteinuria controlling blood pressure with RAS blocking agents 
slows significantly the rate of the decline of the glomerular filtration rate (GFR). 
Other cardiovascular risk factors also play important roles in the progressive renal disease. 
Beside hypertension, smoking (Orth 2000), obesity or hyperlipidemia has not been 
intensively investigated in the early stages of renal disease. Usually hyperlipidemia is 
thought to be associated more with ongoing atherosclerotic process. Nevertheless, 
experimental studies have been shown that lipid abnormalities themselves can influence the 
progression of renal disease and lipid oxidation is increased in animal  and human 
glomerular disease. Increased nephron oxygen radical generation leads to renal tissue lipid 
peroxidation. On the other hand, antioxidative therapy has been shown to be effective on 
antioxidative status in experimental diabetes and in human hypertension. Antilipemic 
therapy may also be beneficial in ameliorating renal disease progression. 
It has been shown that the inhibition of TGF-β leads to the protection of scarring in 
experimental kidney diseass. The modulation of the human renal disease process with 
inhibiting directly particular cytokine upregulation or even prevent fibrotic events, awaits 
future confirmation studies. 
The concept of nephro- or renoprotection  as a definitive proof of ACEI for superior efficacy 
on systemic and intraglomerular pressure, proteinuria and renal disease progression was 
not defined until the results of clinical trials became available. It is proposed that in treating 
hypertension we should aim at reducing systemic blood pressure together with an attempt 
to reduce intraglomerular pressure using the agents that act predominantly on post-
glomerular resistance in order to have renal protection. Both RAS blocking drugs, ACEI and 
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AT1RA have achieved these parameters, and the renoprotective effect includes their impact 
on the hemodynamics, on the reduction of the filtration of plasma proteins, on the 
preservation of kidney function as well as the structure. Therefore, these agents have 
already been accepted in the treatment of diabetic and non-diabetic nephropathies in order 
to arrest and/or prevent renal damage. 
There is convincing evidence that beside diuretics, adrenoblocking agents, beta-blockers, 
calcium channel blockers and other antihypertensive medications, administration of RAS 
blocking agents promise better control of glomerular hypertension and long-term outcome of 
kidney preservation than other agents. Moreover, experimental  as well as clinical data suggest 
that ACEI reduce proteinuria and retard the progression of the renal disease to a greater 
degree than can be explained by their blood pressure lowering effects alone. Effective blockade 
of RAS with ACEI preventing sustained elevation of systemic blood pressure, lowering 
intracapillary pressure, lowering proteinuria modulating hyperlipidemia and inhibition of 
renal growth have been shown to reduce kidney injury and protect the kidney even further 
during the ongoing disease process. The ACEI, by decreasing angiotensin II generation, induce 
glomerular efferent arteriolar dilation as well as mesangial relaxation. These combined effects 
explain a reduced glomerular capillary pressure. The fall in filtration pressure contributes to 
the antiproteinuric effect and also to the long-term renoprotection. 
Glomerulosclerosis and interstitial fibrosis that accompany experimental and human 
glomerulopathies  can also be ameliorated by ACEI or AT1RA administration. Proteinuria 
itself is involved in the final common pathway of the progressive renal function loss. It has 
been hypothesized that the presence of large quantities of protein within the tubules may 
have a damaging effect on the tubular cells and interstitium. This is particularly relevant 
since attention has recently been focused on a well-known but an ignored fact that the 
progression of renal disease best correlates with the extent of interstitial damage and not 
with glomerulosclerosis per se. Remuzzi et al. have summarized the evidence that the 
process of reabsorption of filtered proteins activates the proximal tubular epithelium 
(Remuzzi, Ruggenenti et al. 1997).  
Most experimental studies that compared the effects of ACEI and AT1RA have shown a striking 
similarity of actions between these classes of drugs. Similarly, the effect of ACEI, AT1RA has also 
been shown to lower the systemic and intraglomerular pressure as well as proteinuria and 
morphological lesions. Combination therapy with ACEI and AT1RA is similar to those of 
enalapril or losartan alone and are related to the magnitude of their systemic antihypertensive 
effects (Ots, Mackenzie et al. 1998). These results indicate that both ACEI and AT1RA can lower 
blood pressure at least as effectively as ACE inhibitors and also be renoprotective. In diabetic and 
non-diabetic patients with proteinuria controlling blood pressure with RAS blocking agents 
slows significantly the rate of the decline of the glomerular filtration rate (GFR) (Mogensen, 
Keane et al. 1995). Moreover, the treatment has good effect also for cardiovascular outcome of 
patients with CKD(Brenner, Cooper et al. 2001). In conclusion, many recent experimental and 
clinical studies have shown that besides the systemic blood pressure lowering effect, RAS 
blocking agents provide renal protective effects via direct, hemodynamic, and indirect, non-
hemodynamic, pathways: (1) lowering intraglomerular capillary hydraulic pressure, and 
increasing the glomerular ultrafiltration coefficient; (2) lowering proteinuria; (3) lowering 
hyperlipidemia; (4) diminishing kidney growth; (5) diminishing infiltration of macrophages; 
(6) downregulation of proinflammatory cytokines. Therefore, RAS blocking agents are widely 
prescribed not only for antihypertensive but also for renoprotective purposes in diabetic and 
 
non-diabetic nephropathies. In order to slow to the greatest extent progression of renal disease, 
the ideal therapeutic approach for patients with proteinuric nephropathies should be a 
multimodal strategy including dual RAS blockade, antialdosterone therapy, lipid-lowering 
agents, smoking cessation, and tight glucose control for diabetes. 
 
5. Management of CKD patients 
Clinical evaluation for CKD should include elucidation of the cause of disease. Also, for 
determining the stage and specific characteristics of the underlying disease follow-up of 
patients and thorough diagnostic work-up is needed. However, the cause of the disease 
cannot be ascertained in all cases because renal function declines also normally with age and 
the exact level of decline at a given age that should be considered pathological is not known.  
Cross-sectional studies report a slow decline in GFR after the fourth decade of life ~ 0.75 
mL/min./1.73 m2/year. These changes proceed slowly but in the presence of other diseases 
such as diabetes, hypertension and heart disease, the kidney becomes vulnerable to failure 
(Pannu and Halloran 2001). The KD:IGO (Kidney Disease: Improving Global Outcomes) 
statement considers GFR less than 60 mL/minute pathological at all ages. CKD is classified 
according to severity, diagnosis, treatment and prognosis. Five-stage classification is based 
on structural and functional criteria regardless of the cause and accounting for dialysis and 
transplantation (Gregorio, Obrador et al. 2007). 
The National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) 
workgroup has defined CKD as the following (2002), which have been accepted internationally 
with some clarifications (Levey, Eckardt et al. 2005; Gregorio, Obrador et al. 2007): 
1 The presence of markers of kidney damage for 3 months, as defined by structural or 
functional abnormalities of the kidney with or without decreased glomerular 
filtration rate (GFR), that can lead to decreased GFR, manifest by either pathological 
abnormalities or other markers of kidney damage, including abnormalities in the 
composition of blood or urine, or abnormalities in imaging tests  
2 Or the presence of GFR<60 mL/min./1.73 m2 for 3 months, with or without other 
signs of kidney damage as described above. 
Based upon representative samples of the United States population (2002), the studies have 
estimated the prevalence of CKD in the general population through measurement of 
markers of kidney damage, such as elevated serum creatinine concentration, decreased 
predicted GFR and presence of albuminuria.  
According to the Kidney Disease: Improving Global Outcomes (KD:IGO) position statement 
the use of the term “disease” in CKD is consistent with:  
1) the need for action to improve outcomes through prevention, detection, evaluation 
and treatment;  
2) providing a message for public, physician and patient education programs;  
3) common usage; and 
4) its use in other conditions defined by findings and laboratory tests, such as 
hypertension, diabetes and hyperlipidaemia (Levey, Eckardt et al. 2005). 
CKD is classified according to severity, diagnosis, treatment and prognosis (Levey, Eckardt 
et al. 2005). Five-stage classification is based on structural and functional criteria regardless 
of the cause and accounting for dialysis and transplantation (Table 1).  
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et al. 2005). Five-stage classification is based on structural and functional criteria regardless 
of the cause and accounting for dialysis and transplantation (Table 1).  
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Stage Description GFR (mL/min. per 1.73 m2) Related terms 
1 Kidney damage 
with normal or ↑ 
GFR 
≥ 90 Albuminuria 
Proteinuria 
Haematuria 
2 Kidney damage 
with mild ↓ GFR 
60–89 Albuminuria 
Proteinuria 
Haematuria 
3 Moderate ↓ GFR 30–59 Chronic renal 
insufficiency 
Early renal 
insufficiency 
4 Severe ↓ GFR 15–29 Chronic renal 
insufficiency 
Late renal 
insufficiency 
Pre-ESRD 
5 Kidney failure <15 Renal failure 
Uraemia 
End-stage 
renal disease 
Table 1. Classification of chronic kidney disease.  
 
There is an overwhelming consensus that screening for CKD should include high-risk 
groups. Early detection of diabetes and hypertension as the most important reasons for CKD 
and their appropriate treatment is a method of avoiding or postponing complications, incl. 
chronic kidney failure. Screening of hypertension by measurement of blood pressure at 
office visits has found support in many guidelines. In clinical studies the extent of 
proteinuria correlates with the faster decline of glomerular filtration rate in patients with 
chronic renal diseases. Therefore, strict monitoring of proteinuria helps in the optimal 
management of patients. 
Risk groups of chronic kidney disease are the follows: 
- Patients with a family history of diabetes, hypertension 
- Diabetics 
- Hypertensive patients 
- Recurrent urinary tract infections 
- Urinary obstruction 
- Patients with systemic diseases that affect kidneys 
- Patients with past or family history of cardiovascular disease 
The most widely used methods for screening for kidney disease are: 1) an analysis of a 
random urine sample for albuminuria and, 2) a serum creatinine measurement to calculate 
an estimated GFR, which is an indication of functioning kidney mass. It is recommendable 
to use both of these methods as significant kidney disease can present with diminished GFR 
or proteinuria, or both (Garg, Kiberd et al. 2002). Detecting and quantitation of proteinuria 
are essential to the diagnosis and treatment of CKD. Albumin, the predominant protein 
excreted by the kidney in most types of renal diseases, can be detected by urine dipstick 
testing. The protein-creatinine ratio in an early-morning random urine sample correlates 
 
well with 24-hour urine protein excretion and is much easier to obtain (2002). Albuminuria 
often heralds the onset of diabetic nephropathy, thus this sample is therefore recommended 
for all patients at risk for kidney disease. The quantitative determination of protein in the 
urine in the laboratory is more economical and more correct, than the use of 
microalbuminuria dipsticks and should be the recommended method to detect proteinuria. 
The term “albuminuria” should be substituted for the terms “microalbuminuria” and 
“macroalbuminuria.” These terms are commonly used but should be avoided because they 
are misleading (2005). Increased urinary excretion of albumin is the earliest manifestation of 
CKD due to diabetes, other glomerular diseases and hypertensive nephrosclerosis. Also, 
albuminuria may also accompany tubulointerstitial diseases, polycystic kidney disease and 
kidney disease in transplant recipients. 
Significant kidney dysfunction may be present despite a normal serum creatinine level. An 
estimated GFR based on serum creatinine level correlates better with direct measures of the 
GFR and detects more cases of CKD than does the serum creatinine level alone. Clinically 
useful GFR estimates are calculated from the measured serum creatinine level after 
adjustments for age, sex and race (Cockcroft and Gault 1976; Levey, Bosch et al. 1999). The two 
most commonly used formulas for GFR estimation are the MDRD (Modification of Diet in 
Renal Disease) study equation and the Cockcroft–Gault equation (Table 2). Validation studies 
in middle-aged patients with CKD showed the MDRD study equation to be more accurate 
(Levey, Bosch et al. 1999). However, the MDRD study equation was found to systematically 
underestimate the GFR in patients without CKD. It is important to realise that the 
methodology used for determination of serum creatinine is of great importance in the 
interpretation of the results obtained with the MDRD formula and that in fact, only the IDMS-
corrected serum creatinine can be used (Van Biesen, Vanholder et al. 2006). It should be kept in 
mind that these formulas do not result in correct GFRs when used in persons with abnormal 
body composition: the obese, patients with oedema, pregnancy, states of cachexia or amputees. 
In most situations of family doctors and as long as kidney function is stable, a calculated GFR 
can replace measurement of a 24-hour urine collection for creatinine clearance, that is still 
required in pregnant women, patients with extremes of age and weight, patients with 
malnutrition, patients with musculoskeletal diseases, paraplegia or quadriplegia and patients 
with a vegetarian diet or rapidly changing kidney function (Snyder and Pendergraph 2005). 
Also, creatinine clearance is preferred in predialysis and transplant patients. 
 
Abbreviated MDRD study 
equation (Levey, Bosch et al. 1999) 
GFR (mL per minute per 1.73 m2) = 186 x (SCr)-1.154 x 
(age)-0.203 x (0.742, if female) x (1.210, if black) 
IDMS traceable MDRD formula 
(Van Biesen, Vanholder et al. 
2006) 
GFR (mL per minute per 1.73 m2) = 175 x 
standardised S(Cr)-1.154 x (age)-0.203 x (0.742, if 
female) x (1.212, if black)  
Cockcroft–Gault equation 
(Cockcroft and Gault 1976) 
GFR (mL/min.) =(140 - age) x weight x (0.85, if 
female) 
                                    0.81 x SCr    
GFR = glomerular filtration rate; MDRD = Modification of Diet in Renal Disease;  
SCr = serum creatinine concentration (μmol/L); 
 
Table 2. Estimated glomerular filtration rate mathematical formulas. 
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6. Conclusion 
Glomerular cellular changes such as platelet infiltration, mesangial cell proliferation, 
increased expression of proinflammatory cytokines and growth factors, as well as 
tubulointerstitial changes that occur early in the development of the remnant kidney 
progression and other models of chronic renal insufficiency, were linked to the later 
development of kidney fibrosis. Nowadays, there is evidence that RAS inhibition, besides 
the effects on glomerular hemodynamics, influence other pathogenic mechanisms of 
progressive renal insufficiency, e.g. hypertrophy, proteinuria, hyperlipidemia, kidney 
growth, infiltration of macrophages, expression of proinflammatory cytokines, etc. As 
previously shown in animal and clinical studies, RAS blocking agents effectively affect those 
pathogenetical processes of the progression of renal disease which are not unique but are 
similar for certain nephropathy, and, therefore, deserve to be referred to as renoprotection 
drugs. This is a new concept that came together with the introduction of ACEI in the mid-
1980s in conjunction with their effect on glomerular hemodynamics in experimental settings 
and, later, in clinical works. 
In human chronic renal diseases, the RAS blocking therapy can arrest the decline of the GFR 
in diabetics and non-diabetics. When to start the treatment and which dose to choose? The 
optimal dose has not been determined yet. In experimental studies, optimal dosing and 
timing the treatment is easy to determine. In the cases of human chronic renal diseases 
where the onset of the disease is often insidious and at the time of renal biopsy the disease is 
often already advanced, uncertainty still persists with respect to the relative indications for 
early RAS blockade, especially if the patient does not have hypertension. A better 
understanding of the pathomechanisms of renal disease progression may allow us to 
develop more precise laboratory tests for early diagnosis of various nephropathies. Thus, 
usage of protein and gene expression techniques in renal biopsies or new serum or urine 
tests may afford, in future probably, more accurate detection of early renal alterations. 
Today we have mainly descriptive data about the relevance of these factors in human 
chronic renal diseases and much work waits before molecular diagnosis becomes available. 
Knowledge about the pathogenesis of renal disease progression, the use of more precise 
methods for evaluating renal disease evolution and the determination of the disease stage 
may lead to better control of the progression of renal disease in future and, as a result, 
reduce the number of patients reaching end-stage renal failure. 
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6. Conclusion 
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pathogenetical processes of the progression of renal disease which are not unique but are 
similar for certain nephropathy, and, therefore, deserve to be referred to as renoprotection 
drugs. This is a new concept that came together with the introduction of ACEI in the mid-
1980s in conjunction with their effect on glomerular hemodynamics in experimental settings 
and, later, in clinical works. 
In human chronic renal diseases, the RAS blocking therapy can arrest the decline of the GFR 
in diabetics and non-diabetics. When to start the treatment and which dose to choose? The 
optimal dose has not been determined yet. In experimental studies, optimal dosing and 
timing the treatment is easy to determine. In the cases of human chronic renal diseases 
where the onset of the disease is often insidious and at the time of renal biopsy the disease is 
often already advanced, uncertainty still persists with respect to the relative indications for 
early RAS blockade, especially if the patient does not have hypertension. A better 
understanding of the pathomechanisms of renal disease progression may allow us to 
develop more precise laboratory tests for early diagnosis of various nephropathies. Thus, 
usage of protein and gene expression techniques in renal biopsies or new serum or urine 
tests may afford, in future probably, more accurate detection of early renal alterations. 
Today we have mainly descriptive data about the relevance of these factors in human 
chronic renal diseases and much work waits before molecular diagnosis becomes available. 
Knowledge about the pathogenesis of renal disease progression, the use of more precise 
methods for evaluating renal disease evolution and the determination of the disease stage 
may lead to better control of the progression of renal disease in future and, as a result, 
reduce the number of patients reaching end-stage renal failure. 
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